您当前的位置：

Doxorubicin

(Synonyms: 阿霉素; Hydroxydaunorubicin)

目录号: PC10286 纯度: ≥98%

Doxorubicin 是一种有细胞毒性的蒽环类抗生素，用于治疗多种癌症。 Doxorubicin 在癌细胞中起作用的可能机制是嵌入 DNA 和破坏 topoisomerase-II 介导的DNA修复。

CAS No. :23214-92-8

商品编号	规格	价格	会员价
PC10286-10mg	10mg	¥317.00	请登录
PC10286-25mg	25mg	¥510.00	请登录
PC10286-100mg	100mg	¥1315.00	请登录
PC10286-10mM (in 1mL DMSO)	10mM (in 1mL DMSO)	¥750.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Doxorubicin
中文别名	阿霉素;羟基柔红霉素;亚法里亚霉素;羟基红比霉素;14-羟正定霉素;多柔比星;阿霉素,BR;阿霉素盐酸盐;多柔比星标准品;10-((3-氨基-2,3,6-三去氧-alpha-L-来苏-己吡喃基)氧)-7,8,9,10-四氢-6,8,11-三羟基-8-羟乙酰基-1-甲氧基-5,12-萘二酮
英文名称	Doxorubicin
英文别名	Adriamycin;10-((3-Amino-2,3,6-trideoxy-alpha-L-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;14-Hydroxydaunomycin;(8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione;adiblastine (hydrochloride salt);adriablastine (hydrochloride salt);adriablatina (hydrochloride salt);Adriacin;Adriacin (hydrochloride salt);Adriamycin PFS;Adriamycin PFS (hydrochloride salt);Adriamycin RDF;Adriamycin RDF (hydrochloride salt);Adriblastin;Adriblastina;Adriblastina (hydrochloride salt);adriblatina (hydrochloride salt);Doxorubicin;Doxorubicin hydrochloride (hydrochloride salt);Farmablastina (hydrochloride salt);Hydroxydaunomycin hydrochloride (hydrochloride salt);Hydroxydaunorubicin hydrochloride (hydrochloride salt);Rubex;Rubex (hydrochloride salt);(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen;ADRIAMYCIN ,UP26 CP2005;Doxorubicin (Adriamycin, Dox,NSC 123127,14-Hydroxydaunomycin, 14-Hydroxydaunorubicine);[14C]-Doxorubicin;[3H]-Doxorubicin;adriamycine;Doxil;Hydroxydaunorubicin;(1S,3S)-3,5,12-Trihydroxy-3-(hydroxyac;(1S,3S)-3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;Hydroxydaunomycin hydrochloride
Cas No.	23214-92-8
分子式	C₂₇H₂₉NO₁₁
分子量	543.52
包装储存	4°C, sealed storage, away from moisture and light
详情描述	Doxorubicin 是一种有细胞毒性的蒽环类抗生素，用于治疗多种癌症。 Doxorubicin 在癌细胞中起作用的可能机制是嵌入 DNA 和破坏 topoisomerase-II 介导的DNA修复。

产品详情	Doxorubicin 是一种有细胞毒性的蒽环类抗生素，用于治疗多种癌症。 Doxorubicin 在癌细胞中起作用的可能机制是嵌入 DNA 和破坏 topoisomerase-II 介导的DNA修复。
生物活性	Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].
性状	固体
体外研究(In Vitro)	Doxorubicin hydrochloride (1-8 μM；24 和 48 小时) 以时间和剂量依赖性方式降低 MCF-10F、MCF-7 和 MDA-MB-231 细胞的活力[4]。 Doxorubicin hydrochloride (1 μM；3 和 24 小时) 导致 Hct-116 人结肠癌细胞在 G0/G1 期减少和在 G2 期积累[5]。 Doxorubicin hydrochloride (MCF-10F 和 MDA-MB-231 细胞为 1 μM，MCF-7 细胞为 4 μM；48 小时) 通过上调 Bax、caspase-8 和 caspase-3 以及下调 Bcl-2 蛋白表达诱导细胞凋亡[4]。 Doxorubicin hydrochloride (5 μM; 10-30 分钟) 在 B16-F10 黑色素瘤细胞系 CRL-6475 细胞中能以时间依赖方式在细胞中积累，且可以通过绿色或红色荧光来进行检测 (绿色荧光的检测灵敏度更高), 最大激发波长 (λex) 和最大发射波长 (λem) 分别为 470 nm 和 560 nm[8]。注意： Doxorubicin hydrochloride 适合中性或者弱酸性的溶剂，不建议使用 PBS (PH 7.4) 进行溶解，可能会影响溶解效果。
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	4°C, sealed storage, away from moisture and light
结构分类	Quinones Anthraquinones
参考文献	[1]. John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [Content Brief] [2]. Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. [Content Brief] [3]. P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. [Content Brief] [4]. Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62. [Content Brief] [5]. Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21. [Content Brief] [6]. Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. [Content Brief] [7]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9 [Content Brief] [8]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830. [Content Brief] [9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [Content Brief]

[2]. Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. [Content Brief]

[3]. P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. [Content Brief]

[4]. Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62. [Content Brief]

[5]. Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21. [Content Brief]

[6]. Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. [Content Brief]

[7]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9 [Content Brief]

[8]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830. [Content Brief]

[9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Doxorubicin

相关文献

相关产品

The molarity calculator equation

The dilution calculator equation